GlassScriptPhysician profile
Stephen J Watts
NPI 1639261506
$14,817.33
in general payments reported to CMS, 2019-2025
37 companies · $3,552 in 2025
The $3,552 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $1,520 · 2021: $1,876 · 2022: $2,936 · 2023: $1,981 · 2024: $2,046 · 2025: $3,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,578.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,454.72 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,574.89 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,072.59 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $865.24 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $693.53 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $672.22 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $610.07 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $557.77 | 2020-2024 | Ocaliva |
| Gilead Sciences, INC. | $526.80 | 2019-2025 | Epclusa, Livdelzi |
| Pfizer INC. | $444.37 | 2020-2025 | |
| Medtronic, INC. | $360.26 | 2022-2024 | Gi Genius, Interstim |
| Genzyme Corporation | $328.45 | 2022-2025 | |
| Romark Laboratories, Lc | $232.31 | 2019-2020 | |
| Lilly USA, LLC | $230.57 | 2022-2025 | Omvoh |
| Qol Medical, LLC | $221.34 | 2019-2024 | Sucraid |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $220.07 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $173.96 | 2019-2025 | Tremfya |
| Aimmune Therapeutics, INC. | $163.17 | 2024-2025 | Zenpep, Vowst |
| Ambu INC. | $150.02 | 2020 | |
| Erbe USA INC | $135.85 | 2022 | |
| Daiichi Sankyo INC. | $124.70 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $124.10 | 2024-2025 | Voquezna |
| Pentax of America, INC. | $117.69 | 2022 | |
| Nestle Healthcare Nutrition INC. | $96.73 | 2021-2023 | |
| Novo Nordisk INC | $89.09 | 2025 | Wegovy |
| Merit Medical Systems INC | $86.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $79.77 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $76.11 | 2024-2025 | Iqirvo, Bylvay |
| Vivus LLC | $70.40 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.04 | 2020-2021 | |
| Capsovision, INC. | $58.38 | 2023 | Capsocam Plus |
| Evoke Pharma, INC. | $42.59 | 2020-2021 | |
| Redhill Biopharma INC. | $24.14 | 2023 | Talicia |
| Boston Scientific Corporation | $21.67 | 2023 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $21.39 | 2023 | Amplatzer Amulet |
| Concordia Pharmaceuticals INC. | $14.83 | 2019 | |
| Ucb, INC. | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.